MXPA04002084A - Metodo para la identificacion de antigenos de polipeptidos asociados con desordenes que involucran la proliferacion de celulas aberrantes, y las composiciones utiles para el tratamiento de tales desordenes. - Google Patents
Metodo para la identificacion de antigenos de polipeptidos asociados con desordenes que involucran la proliferacion de celulas aberrantes, y las composiciones utiles para el tratamiento de tales desordenes.Info
- Publication number
- MXPA04002084A MXPA04002084A MXPA04002084A MXPA04002084A MXPA04002084A MX PA04002084 A MXPA04002084 A MX PA04002084A MX PA04002084 A MXPA04002084 A MX PA04002084A MX PA04002084 A MXPA04002084 A MX PA04002084A MX PA04002084 A MXPA04002084 A MX PA04002084A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disorders
- antibodies
- polypeptide antigens
- mitotic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se dan a conocer metodos y composiciones para el desarrollo de terapias efectivas contra el cancer, que usan inhibidores mitoticos, los cuales tienen una toxicidad general limitada a las celulas y tejidos normales, no cancerosos. Estos metodos y composiciones utilizan compuestos citotoxicos comprendidos de un agente que se une a la celula (por ejemplo, anticuerpos), conjugados a un compuesto anti-mitotico (por ejemplo los maytansinoides) . La invencion ademas proporciona anticuerpos que son sustancialmente incapaces de inducir la citotoxicidad mediada por la celula, dependiente del anticuerpo (ADCC) y/o citotoxicidad dependiente del complemente (CDC), asegurando asi que el efecto terapeutico sea mediado primariamente por el componente anti-mitotico del compuesto citotoxico, mas bien que por la muerte celular indirecta por medio de la ADCC y/o la CDC. Los anticuerpos de la invencion ademas son capaces de diferenciar entre los antigenos del polipeptido que son expresados mas altamente en las celulas del cancer que proliferan, en comparacion con las celulas del cancer que proliferan.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31750401P | 2001-09-05 | 2001-09-05 | |
| PCT/US2002/028176 WO2003020909A2 (en) | 2001-09-05 | 2002-09-04 | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04002084A true MXPA04002084A (es) | 2004-06-07 |
Family
ID=23233944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04002084A MXPA04002084A (es) | 2001-09-05 | 2002-09-04 | Metodo para la identificacion de antigenos de polipeptidos asociados con desordenes que involucran la proliferacion de celulas aberrantes, y las composiciones utiles para el tratamiento de tales desordenes. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1432446B1 (es) |
| JP (2) | JP5224632B2 (es) |
| KR (3) | KR20040044850A (es) |
| CN (2) | CN1578673A (es) |
| AT (1) | ATE506965T1 (es) |
| AU (1) | AU2002332838B2 (es) |
| BR (1) | BR0212641A (es) |
| CA (1) | CA2457541C (es) |
| DE (1) | DE60239881D1 (es) |
| DK (1) | DK1432446T3 (es) |
| HU (1) | HUP0500617A3 (es) |
| IL (2) | IL160659A0 (es) |
| MX (1) | MXPA04002084A (es) |
| NZ (1) | NZ531515A (es) |
| PL (1) | PL374363A1 (es) |
| WO (1) | WO2003020909A2 (es) |
| ZA (1) | ZA200401751B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8088387B2 (en) * | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| PT3524611T (pt) * | 2003-05-20 | 2021-04-01 | Immunogen Inc | Agentes citotóxicos melhorados compreendendo novos maitansinóides |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| NO347360B1 (no) * | 2003-10-10 | 2023-09-25 | Immunogen Inc | Cellebindingsmiddelmaytansinoid-konjugat med formel trastuzumab-SMCC-DM1 eller trastuzumab-SIABDM1, fremgangsmåte for fremstilling av disse og en in vitro fremgangsmåte for å styre maytansinoider til en valgt cellepopulasjon eller for å eliminere celler, samt anvendelse. |
| PL2247304T3 (pl) * | 2008-04-02 | 2017-01-31 | Macrogenics, Inc. | Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| IL144559A0 (en) * | 1999-03-01 | 2002-05-23 | Genentech Inc | Antibodies for cancer therapy and diagnosis |
| DE60039448D1 (de) * | 1999-10-29 | 2008-08-21 | Genentech Inc | Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung |
| MXPA02007317A (es) * | 2000-01-26 | 2004-07-30 | Ventana Med Syst Inc | Un sistema para desarrollar ensayos para medicina personalizada. |
-
2002
- 2002-09-04 KR KR10-2004-7003327A patent/KR20040044850A/ko not_active Application Discontinuation
- 2002-09-04 DK DK02797854.3T patent/DK1432446T3/da active
- 2002-09-04 CN CNA02821529XA patent/CN1578673A/zh active Pending
- 2002-09-04 KR KR1020107011044A patent/KR20100061863A/ko not_active Application Discontinuation
- 2002-09-04 NZ NZ531515A patent/NZ531515A/en not_active IP Right Cessation
- 2002-09-04 CA CA2457541A patent/CA2457541C/en not_active Expired - Fee Related
- 2002-09-04 WO PCT/US2002/028176 patent/WO2003020909A2/en active Application Filing
- 2002-09-04 MX MXPA04002084A patent/MXPA04002084A/es active IP Right Grant
- 2002-09-04 AU AU2002332838A patent/AU2002332838B2/en not_active Ceased
- 2002-09-04 DE DE60239881T patent/DE60239881D1/de not_active Expired - Lifetime
- 2002-09-04 IL IL16065902A patent/IL160659A0/xx unknown
- 2002-09-04 EP EP02797854A patent/EP1432446B1/en not_active Expired - Lifetime
- 2002-09-04 HU HU0500617A patent/HUP0500617A3/hu unknown
- 2002-09-04 KR KR1020097019746A patent/KR20090104925A/ko not_active Application Discontinuation
- 2002-09-04 PL PL02374363A patent/PL374363A1/xx not_active IP Right Cessation
- 2002-09-04 AT AT02797854T patent/ATE506965T1/de not_active IP Right Cessation
- 2002-09-04 CN CNA2008101656506A patent/CN101446590A/zh active Pending
- 2002-09-04 JP JP2003525613A patent/JP5224632B2/ja not_active Expired - Fee Related
- 2002-09-04 BR BR0212641-9A patent/BR0212641A/pt active Pending
-
2004
- 2004-03-01 IL IL160659A patent/IL160659A/en not_active IP Right Cessation
- 2004-03-03 ZA ZA2004/01751A patent/ZA200401751B/en unknown
-
2010
- 2010-08-04 JP JP2010175090A patent/JP2010280691A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1432446B1 (en) | 2011-04-27 |
| ATE506965T1 (de) | 2011-05-15 |
| EP1432446A4 (en) | 2004-09-08 |
| WO2003020909A3 (en) | 2003-11-20 |
| CA2457541C (en) | 2013-01-08 |
| JP5224632B2 (ja) | 2013-07-03 |
| KR20040044850A (ko) | 2004-05-31 |
| EP1432446A2 (en) | 2004-06-30 |
| IL160659A (en) | 2011-07-31 |
| HUP0500617A2 (hu) | 2005-10-28 |
| CN1578673A (zh) | 2005-02-09 |
| CA2457541A1 (en) | 2003-03-13 |
| NZ531515A (en) | 2007-11-30 |
| BR0212641A (pt) | 2005-04-12 |
| PL374363A1 (en) | 2005-10-17 |
| AU2002332838B2 (en) | 2007-08-02 |
| WO2003020909A2 (en) | 2003-03-13 |
| IL160659A0 (en) | 2004-08-31 |
| ZA200401751B (en) | 2005-07-27 |
| DE60239881D1 (de) | 2011-06-09 |
| JP2005517155A (ja) | 2005-06-09 |
| DK1432446T3 (da) | 2011-07-18 |
| HUP0500617A3 (en) | 2012-05-02 |
| KR20090104925A (ko) | 2009-10-06 |
| JP2010280691A (ja) | 2010-12-16 |
| KR20100061863A (ko) | 2010-06-09 |
| CN101446590A (zh) | 2009-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3057297A (en) | Targeted combination immunotherapy of cancer | |
| EP1551812A4 (en) | MITOTIC KINESINE HEMMER | |
| EP1481077A4 (en) | MITOTIC KINESINE HEMMER | |
| WO2003050064A3 (en) | Mitotic kinesin inhibitors | |
| WO2003049527A3 (en) | Mitotic kinesin inhibitors | |
| WO2003050122A3 (en) | Mitotic kinesin inhibitors | |
| WO2005009389A3 (en) | Anaplastic lymphoma kinase modulators and methods of use | |
| WO2007053573A3 (en) | Treatment of cancer with sorafenib | |
| WO2008091620A3 (en) | Combination therapy comprising romidepsin and i.a. bortezomib | |
| WO2005013996A3 (en) | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | |
| MXPA04002070A (es) | Compuestos de indazol sustituidos para el tratamiento de la inflamacion. | |
| AU2001233726A1 (en) | Farnesyl protein transferase inhibitors for treating breast cancer | |
| WO2005085188A3 (en) | Compounds and methods for anti-tumor therapy | |
| WO2004089294A3 (en) | Compositions, methods and kits relating to her-2 cleavage | |
| WO2000051548A3 (en) | COMPOSITIONS AND METHODS FOR THEIR PREPARATION FROM $i(LEPIDIUM) | |
| WO2005065183A3 (en) | Mitotic kinesin inhibitors | |
| EP1453812A4 (en) | CYTOTOXIC AGENTS | |
| WO2004028474A3 (en) | Caspase inhibitors as anticancer agents | |
| WO2002080854A3 (en) | Compositions and methods for the prevention and treatment of human prostate cancer | |
| IL160659A0 (en) | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders | |
| AU2002350623A1 (en) | Targeted thrombosis by tissue factor polypeptides | |
| MX2022013393A (es) | Receptores de antígenos quiméricos dirigidos a cd19 y uso de los mismos. | |
| WO2002020000A3 (en) | Combined estrogen blockade of the breast with exemestane and raloxifene | |
| BR0116123A (pt) | Carbazóis antitumorais | |
| WO2003077874A3 (en) | Substituted tetrahydroisoquinoline compounds, methods of making, and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |